Compare SCM & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCM | SLDB |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 397.8M | 444.9M |
| IPO Year | 2012 | 2018 |
| Metric | SCM | SLDB |
|---|---|---|
| Price | $12.30 | $6.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $13.00 | ★ $14.70 |
| AVG Volume (30 Days) | 171.7K | ★ 999.5K |
| Earning Date | 03-03-2026 | 03-05-2026 |
| Dividend Yield | ★ 11.10% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.09 | N/A |
| Revenue | ★ $102,538,895.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.21 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.19 | $2.41 |
| 52 Week High | $15.56 | $7.37 |
| Indicator | SCM | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 36.96 | 60.93 |
| Support Level | $12.10 | $6.29 |
| Resistance Level | $13.11 | $6.63 |
| Average True Range (ATR) | 0.31 | 0.36 |
| MACD | -0.11 | 0.03 |
| Stochastic Oscillator | 11.72 | 76.33 |
Stellus Capital Investment Corp is a closed-end, non-diversified management investment company. Its objective is to maximize the total return to its stockholders in the form of current income and capital appreciation. It invests in private middle-market companies through a first lien, second lien, and unsecured debt financing, often with a corresponding equity investment. The company invests in various sectors, such as business services, energy, general industrial, government services, healthcare, software, and specialty finance. The business activity of the firm is functioned through the United States and it generates revenue in the form of interest income on debt investments and capital gains and distributions.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.